These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 19038008)
1. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy. Maeshima AM; Taniguchi H; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y Cancer Sci; 2009 Jan; 100(1):54-61. PubMed ID: 19038008 [TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
3. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature. Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184 [TBL] [Abstract][Full Text] [Related]
4. Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab. Seliem RM; Freeman JK; Steingart RH; Hasserjian RP Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):18-23. PubMed ID: 16540725 [TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy. Maeshima AM; Taniguchi H; Fujino T; Saito Y; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Izutsu K Ann Hematol; 2020 Sep; 99(9):2141-2148. PubMed ID: 32451711 [TBL] [Abstract][Full Text] [Related]
6. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. Kennedy GA; Tey SK; Cobcroft R; Marlton P; Cull G; Grimmett K; Thomson D; Gill D Br J Haematol; 2002 Nov; 119(2):412-6. PubMed ID: 12406079 [TBL] [Abstract][Full Text] [Related]
8. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy. Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122 [TBL] [Abstract][Full Text] [Related]
9. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Piro LD; White CA; Grillo-López AJ; Janakiraman N; Saven A; Beck TM; Varns C; Shuey S; Czuczman M; Lynch JW; Kolitz JE; Jain V Ann Oncol; 1999 Jun; 10(6):655-61. PubMed ID: 10442187 [TBL] [Abstract][Full Text] [Related]
10. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan. Tobinai K Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S85-90. PubMed ID: 11587374 [TBL] [Abstract][Full Text] [Related]
11. Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome. Goteri G; Olivieri A; Ranaldi R; Lucesole M; Filosa A; Capretti R; Pieramici T; Leoni P; Rubini C; Fabris G; Lo Muzio L Int J Immunopathol Pharmacol; 2006; 19(2):421-31. PubMed ID: 16831308 [TBL] [Abstract][Full Text] [Related]
12. Loss of CD20 expression in relapsed lymphomas after rituximab therapy. Haidar JH; Shamseddine A; Salem Z; Mrad YA; Nasr MR; Zaatari G; Bazarbachi A Eur J Haematol; 2003 May; 70(5):330-2. PubMed ID: 12694172 [TBL] [Abstract][Full Text] [Related]
13. [Rituximab resistance in B-cell lymphoma and its elimination]. Hatake K; Terui Y Gan To Kagaku Ryoho; 2009 Apr; 36(4):548-51. PubMed ID: 19381025 [TBL] [Abstract][Full Text] [Related]
14. Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases. Fierro MT; Savoia P; Quaglino P; Novelli M; Barberis M; Bernengo MG J Am Acad Dermatol; 2003 Aug; 49(2):281-7. PubMed ID: 12894078 [TBL] [Abstract][Full Text] [Related]
16. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Marcus R; Hagenbeek A Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982 [TBL] [Abstract][Full Text] [Related]
17. Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials. Griffin MM; Morley N Expert Opin Biol Ther; 2013 May; 13(5):803-11. PubMed ID: 23560506 [TBL] [Abstract][Full Text] [Related]
18. Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl. Culić S; Culić V; Armanda V; Kuljis D; Pesutić-Pisac V; Janković S Pediatr Hematol Oncol; 2003 Jun; 20(4):339-44. PubMed ID: 12746167 [TBL] [Abstract][Full Text] [Related]
19. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463 [TBL] [Abstract][Full Text] [Related]
20. CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection. Pijuan L; Vicioso L; Bellosillo B; Ferrer MD; Baró T; Pedro C; Lloreta-Trull J; Munné A; Serrano S Am J Surg Pathol; 2005 Oct; 29(10):1399-403. PubMed ID: 16160485 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]